A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0873 in Rheumatoid Arthritis.

Trial Profile

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0873 in Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2014

At a glance

  • Drugs MK 0873 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Nov 2009 Actual patient number (106) added and official title amended as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top